McPherron Aviva 4
4 · Orthofix Medical Inc. · Filed Mar 6, 2026
Research Summary
AI-generated summary of this filing
Orthofix (OFIX) President Aviva McPherron Sells Shares
What Happened
- Aviva McPherron, President, Global Operations & Quality at Orthofix (OFIX), disposed of 2,559 shares in two open-market sell transactions tied to the settlement of restricted stock units (RSUs).
- 2026-03-04: 1,296 shares at $12.92 — proceeds $16,740 (weighted-price range reported 12.80–13.03).
- 2026-03-05: 1,263 shares at $12.55 — proceeds $15,852 (weighted-price range reported 12.48–12.72).
- Total proceeds: approximately $32,592. These sales were sell-to-cover transactions to satisfy tax withholding on vested RSUs, not discretionary trades.
Key Details
- Transaction codes: S = Sale; these were not purchases.
- Dates: March 4 and March 5, 2026; Form 4 filed March 6, 2026 (timely).
- Shares owned after transaction: not explicitly stated in the filing; filing notes inclusion of 54,692 previously reported RSUs.
- Footnotes:
- F1 — Sales were to satisfy tax withholding on RSU settlement per a board-approved sell-to-cover requirement; sale made without the reporting person's discretion.
- F2/F4 — Prices are weighted averages; ranges given for the multiple executions.
- F3 — Reference to 54,692 previously reported restricted stock units.
Context
- These were routine sell-to-cover transactions tied to compensation (RSU vesting) and are generally administrative (to cover taxes), not a clear signal of insider sentiment. Purchases would carry more weight as a bullish signal; this filing documents tax-related disposals executed under a pre-existing mandate.
Insider Transaction Report
Form 4
McPherron Aviva
Pres, Global Ops & Qual
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-03-04$12.92/sh−1,296$16,740→ 69,116 total - Sale
Common Stock
[F1][F4][F3]2026-03-05$12.55/sh−1,263$15,852→ 67,853 total
Footnotes (4)
- [F1]Represents the number of shares of common stock sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units, pursuant to a pre-existing sell-to-cover requirement previously approved and mandated by the Compensation and Talent Development Committee of the Company's Board of Directors (the administrator of the plan pursuant to which such restricted stock units were granted). Such sale was made without the exercise of any discretion by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.03, inclusive. The reporting person undertakes to provide to Orthofix Medical Inc., any security holder of Orthofix Medical Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4.
- [F3]Includes 54,692 previously reported restricted stock units.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.48 to $12.72, inclusive.
Signature
/s/ J. Andres Cedron, Attorney-in-fact|2026-03-06